

Geert J L H Van Leenders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8223245/publications.pdf>

Version: 2024-02-01

102
papers

3,719
citations

136740

32
h-index

143772

57
g-index

103
all docs

103
docs citations

103
times ranked

5676
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, e87-e99.	2.1	292
2	A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial. <i>Journal of Urology</i> , 2011, 185, 121-125.	0.2	248
3	Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. <i>Modern Pathology</i> , 2015, 28, 457-464.	2.9	239
4	Polycomb-Group Oncogenes EZH2, BMI1, and RING1 Are Overexpressed in Prostate Cancer With Adverse Pathologic and Clinical Features. <i>European Urology</i> , 2007, 52, 455-463.	0.9	166
5	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	1.4	152
6	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
7	A Prostate Cancer "Nimbus" Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	0.9	142
8	Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels. <i>Journal of Virology</i> , 2016, 90, 4838-4842.	1.5	107
9	Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. <i>Modern Pathology</i> , 2011, 24, 1128-1138.	2.9	106
10	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. <i>BMC Cancer</i> , 2018, 18, 8.	1.1	93
11	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	1.6	82
12	The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men. <i>European Urology</i> , 2014, 66, 1109-1115.	0.9	74
13	Three-dimensional microscopic analysis of clinical prostate specimens. <i>Histopathology</i> , 2016, 69, 985-992.	1.6	71
14	Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. <i>Modern Pathology</i> , 2019, 32, 139-146.	2.9	71
15	Androgen receptor profiling predicts prostate cancer outcome. <i>EMBO Molecular Medicine</i> , 2015, 7, 1450-1464.	3.3	67
16	Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e26753.	1.1	66
17	Identification of <i>TDRD1</i> as a direct target gene of <i>ERG</i> in primary prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 335-345.	2.3	59
18	Disease-specific death and metastasis do not occur in patients with Gleason score ≤ 6 at radical prostatectomy. <i>BJU International</i> , 2015, 116, 230-235.	1.3	57

#	ARTICLE	IF	CITATIONS
19	Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. <i>European Urology</i> , 2020, 77, 191-198.	0.9	57
20	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. <i>European Urology</i> , 2020, 78, 682-687.	0.9	57
21	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	3.0	51
22	Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer. <i>Modern Pathology</i> , 2015, 28, 515-522.	2.9	48
23	The role of HOXC6 in prostate cancer development. <i>Prostate</i> , 2015, 75, 1868-1876.	1.2	43
24	Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. <i>Translational Andrology and Urology</i> , 2018, 7, 132-144.	0.6	43
25	Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. <i>Oncotarget</i> , 2015, 6, 4036-4050.	0.8	42
26	Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer. <i>Oncotarget</i> , 2015, 6, 24488-24498.	0.8	42
27	Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	41
28	Immunoglobulin G4-related Prostatitis: A Case-control Study Focusing on Clinical and Pathologic Characteristics. <i>Urology</i> , 2014, 83, 521-527.	0.5	40
29	PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 538-540.	0.9	40
30	The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. <i>BJU International</i> , 2008, 101, 685-690.	1.3	37
31	Validation of stem cell markers in clinical prostate cancer: $\alpha 6$ -Integrin is predictive for non-aggressive disease. <i>Prostate</i> , 2014, 74, 488-496.	1.2	37
32	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. <i>Modern Pathology</i> , 2015, 28, 695-705.	2.9	37
33	Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. <i>Modern Pathology</i> , 2021, 34, 184-193.	2.9	32
34	The value of EZH2, p27 ^{kip1} , BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. <i>BJU International</i> , 2010, 106, 280-286.	1.3	31
35	Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. <i>Modern Pathology</i> , 2019, 32, 1032-1041.	2.9	30
36	Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?. <i>BJU International</i> , 2020, 126, 124-132.	1.3	30

#	ARTICLE	IF	CITATIONS
37	Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential. <i>European Urology</i> , 2016, 69, 710-719.	0.9	25
38	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 978-985.	1.3	25
39	Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. <i>Histopathology</i> , 2018, 73, 983-989.	1.6	24
40	Relocation of inadequate resection margins in the wound bed during oral cavity oncological surgery: A feasibility study. <i>Head and Neck</i> , 2019, 41, 2159-2166.	0.9	24
41	Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. <i>Histopathology</i> , 2020, 77, 850-861.	1.6	24
42	Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. <i>BJU International</i> , 2009, 104, 321-325.	1.3	23
43	Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. <i>Prostate</i> , 2012, 72, 108-115.	1.2	22
44	Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. <i>Histopathology</i> , 2019, 75, 338-345.	1.6	22
45	Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 249-256.	1.4	22
46	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
47	Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. <i>Oncotarget</i> , 2016, 7, 70669-70684.	0.8	21
48	Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy. <i>American Journal of Surgical Pathology</i> , 2020, 44, 191-197.	2.1	20
49	Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy. <i>Histopathology</i> , 2020, 76, 755-762.	1.6	18
50	MET expression during prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 31029-31036.	0.8	18
51	An activating mutation in <i>AKT1</i> in human prostate cancer. <i>International Journal of Cancer</i> , 2008, 123, 2725-2726.	2.3	17
52	GRPr Antagonist ⁶⁸ Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1517-1523.	2.8	17
53	Automated detection of cribriform growth patterns in prostate histology images. <i>Scientific Reports</i> , 2020, 10, 14904.	1.6	16
54	Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens. <i>Histopathology</i> , 2020, 77, 742-748.	1.6	16

#	ARTICLE	IF	CITATIONS
55	Intraoperative assessment and reporting of radical prostatectomy specimens to guide nerve-sparing surgery in prostate cancer patients (NeuroSAFE). <i>Histopathology</i> , 2020, 77, 539-547.	1.6	15
56	Comparison of RNA extraction kits and histological stains for laser capture microdissected prostate tissue. <i>BMC Research Notes</i> , 2016, 9, 17.	0.6	14
57	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	4.3	14
58	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1007-1007.	2.1	14
59	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 13167-13181.	0.8	14
60	mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 32916-32924.	0.8	14
61	Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. <i>Oncotarget</i> , 2016, 7, 37846-37856.	0.8	14
62	Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach. <i>Journal of Digital Imaging</i> , 2022, 35, 127-136.	1.6	14
63	The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading. <i>European Urology</i> , 2021, 79, 707-709.	0.9	13
64	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. <i>International Journal of Cancer</i> , 2021, 148, 981-987.	2.3	12
65	Primary Cystic Lesions of the Retrorectal Space: MRI Evaluation and Clinical Assessment. <i>American Journal of Roentgenology</i> , 2017, 209, 790-796.	1.0	11
66	Three-dimensional architecture of common benign and precancerous prostate epithelial lesions. <i>Histopathology</i> , 2019, 74, 1036-1044.	1.6	11
67	Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. <i>European Journal of Radiology</i> , 2020, 131, 109266.	1.2	11
68	Clinicopathological characteristics of glomeruloid architecture in prostate cancer. <i>Modern Pathology</i> , 2020, 33, 1618-1625.	2.9	11
69	Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients. <i>Histopathology</i> , 2022, 80, 558-565.	1.6	11
70	<sc>NeuroSAFE</sc> in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome. <i>BJU International</i> , 2022, 130, 628-636.	1.3	11
71	Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0126029.	1.1	10
72	Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. <i>Prostate</i> , 2019, 79, 1032-1042.	1.2	10

#	ARTICLE	IF	CITATIONS
73	Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients. <i>Modern Pathology</i> , 2021, 34, 2064-2070.	2.9	10
74	Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer. <i>Oncotarget</i> , 2018, 9, 36444-36456.	0.8	10
75	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNAâ€™minus RNA sequencing data. <i>GigaScience</i> , 2021, 10, .	3.3	10
76	Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 149-156.	1.4	9
77	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. <i>Annals of Diagnostic Pathology</i> , 2021, 52, 151733.	0.6	9
78	Cysteineâ€™rich secretory protein 3 and Î²â€™microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome. <i>BJU International</i> , 2011, 108, 1356-1362.	1.3	8
79	Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. <i>Histopathology</i> , 2022, 80, 1041-1049.	1.6	8
80	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€™based survey by the European Network of Uropathology. <i>Histopathology</i> , 2019, 74, 844-852.	1.6	7
81	Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. <i>Journal of Personalized Medicine</i> , 2020, 10, 270.	1.1	7
82	EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1650.	1.8	6
83	Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F204-F213.	1.3	6
84	Multi-line fluorescence scanning microscope for multi-focal imaging with unlimited field of view. <i>Biomedical Optics Express</i> , 2019, 10, 6313.	1.5	6
85	Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. <i>American Journal of Clinical Pathology</i> , 2021, 156, 895-905.	0.4	5
86	Antiâ€™PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. <i>Clinical Cancer Research</i> , 2022, 28, 215-226.	3.2	5
87	No evidence of <i>FGFR3</i> mutations in prostate cancer. <i>Prostate</i> , 2011, 71, 637-641.	1.2	4
88	MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma. <i>PLoS ONE</i> , 2020, 15, e0228014.	1.1	3
89	Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth. <i>Annals of Diagnostic Pathology</i> , 2022, 56, 151842.	0.6	3
90	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	2.1	3

#	ARTICLE	IF	CITATIONS
91	Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1149-1157.	1.4	2
92	The impact of the COVID-19 pandemic on bladder cancer care in the Netherlands. <i>Bladder Cancer</i> , 2022, , 1-17.	0.2	2
93	PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 705-713.	1.4	1
94	Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy. <i>European Urology Open Science</i> , 2022, 36, 19-22.	0.2	1
95	Despite extensive efforts, the validation of prognostic tissue markers in prostate cancer has not yet resulted in the widespread implementation of novel diagnostic tests. <i>European Urology</i> , 2007, 52, 125.	0.9	1
96	Predictive Value of Cribriform and Intraductal Carcinoma for the Nomogram-based Selection of Prostate Cancer Patients for Pelvic Lymph Node Dissection. <i>Urology</i> , 2022, 168, 156-164.	0.5	1
97	Editorial Comment on: Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer. <i>European Urology</i> , 2008, 54, 1323.	0.9	0
98	Blaaskankerpathologie: van cystoscoop naar microscoop. <i>Tijdschrift Voor Urologie</i> , 2015, 5, 193-198.	0.1	0
99	Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>Eur Urol</i> 2019;75:538-40. <i>European Urology</i> , 2019, 75, e160-e161.	0.9	0
100	PD-L1 testing in urothelial carcinoma: are we there yet?. <i>Translational Andrology and Urology</i> , 2019, 8, S466-S468.	0.6	0
101	Unique Case of a Rare Mesenchymal Tumor Harboring a Somatic c.119delC VHL Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	0
102	Eight Endorsements of the International Society of Urological Pathology from the 2019 Consensus Conference on Grading of Prostatic Carcinoma. <i>Journal of Urology</i> , 2021, 205, 8-10.	0.2	0